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Transplant-Acquired Food Allergy Following Cord Blood
Transplantation in Adult Patients
TakehikoMori, Jun Kato, Sumiko Kohashi, Shinichiro Okamoto.
Division of Hematology, Keio University School of Medicine,
Tokyo, Japan
Background: The development of new food allergy
after allogeneic hematopoietic stem cell transplantation
(transplant-acquired food allergy: TAFA) has been
sporadically reported. Most of such cases were considered as
the passive transfer of food allergy through allogeneic
hematopoietic stem cell transplantation (HSCT) from donors
already allergic to speciﬁc allergens. Although cord blood
donors are basically considered lacking the known food
allergy, there have been some cases of TAFA following
cord blood transplantation (CBT). Therefore, we have
retrospectively evaluated the adult patients who developed
food allergy after cord blood in a single institute.
Patients and Methods: Among the patients who underwent
CBT for hematological diseases at Keio University Hospital
(Tokyo, Japan), patients survived longer than 30 days after
CBT with donor cell engraftment were selected from the
institutional database. Medical information about food
allergy was retrospectively collected from the medical
records of each patient.
Results: Of the 51 evaluable patients, 3 patients experienced
episodes of new food allergy, in whom food allergy was
deﬁnitely diagnosed based on the results of radioallergo-
sorbent test and/or the retry test. The characteristics of three
patients at transplant are as follows: Case 1, 55-year old male
with myelodysplastic syndrome; Case 2, 57-year-old male
with Sezary syndrome; Case 3, 19-year-old female with
aplastic anemia. All patients received CBT following
ﬂudarabine-based reduced-intensity conditioning regimens
and received cyclosporine A or tacrolimus with or without
short-term methotrexate for graft-versus-host disease
prophylaxis. At 10 months after CBT, Case 1 developed severe
reactions after ingesting egg-containing meal, including skin
rash, shortness of breath, and loss of consciousness. He was
successfully treated with steroid and epinephrine. At 6
months after CBT, Case 2 repeatedly experienced the
episodes of severe reactions after ingesting buckwheat
noodle, including fever, diarrhea, vomiting, and hypotension.
He was successfully treated with massive hydration. At 5
months after CBT, Case 3 repeatedly experienced gastroin-
testinal symptoms such as vomiting and diarrhea after
ingesting egg-containing food. At each episode, she
recovered without any interventions.
Conclusion: Although the incidence is low, acquisition of
new food allergy has been observed within one year after
CBT. By accumulating the cases, the epidemiology and
clinical feature of TAFA following CBT should be further
evaluated.
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Recovery of Endogenous IgG Production Following
Rituximab Treatment after HSCT
Christopher Morris, Joan Morris. Pediatrics, Loma Linda
University, Loma Linda, CA
Rituximab is a monoclonal antibody to the CD20 antigen
expressed on B lymphocytes. Several recent reports suggest
that rituximab may be used to treat complications of SCT
including GVHD and EBV reactivation. The long term
consequences on IgG recovery aren’t well studied. This is aretrospective analysis of allogeneic pediatric SCT patients
treated with rituximab at Loma Linda University from 2004
to 2013. We treated 23 patients with rituximab following
allogeneic SCT (11 MUD, 7 MSD, 3 Cord) for post-transplant
EBV reactivation alone (4), cGVHD alone (4) in combination
with thrombocytopenia (9), hemolysis (4) or EBV
reactivation (2). During and at end of rituximab therapy all
patients required IVIG monthly or more frequently (4) to
maintain serum IgG levels >500mg/dl. We examined the
length of time from end of rituximab therapy to recovery of
endogenous IgG production. The inﬂuence of cGVHD, EBV
infection, type of stem cell graft, and number of doses of
rituximab, on the pace of recovery of endogenous IgG
production was evaluated. Those treated for cGVHD plus any
other indication (n¼19) received a median of 11 doses of
rituximab (range 4 to >30). Among these patients, 11 of 14
whose cGVHD resolved and came off immune suppression
recovered the ability to produce IgG completely (9) or
partially (2, deﬁned as decreasing frequency of IVIG infusions
to maintain IgG>500mg/dl). Median time to recovery was 14
months (range>4 to 50 months) after last dose of rituximab.
For patients who continued to require immune suppression
for cGVHD, only 1 of 5 recovered IgG production (13 months
from last dose) and the other 4 continue to require IVIG at
least monthly for >3 years after the last dose of rituximab.
There were 4 patients treated with 2-4 doses of rituximab for
EBV reactivation early after SCT. Only 1 has completely
recovered IgG production. The other patients remain
dependent on IVIG a median of >39 months since end of
rituximab therapy.
We found no relationship between age of patient or
duration of rituximab therapy on the time interval between
end of rituximab therapy and onset of endogenous IgG
production. Recipients of MUD grafts had a non-signiﬁcant
increase in failure to recover endogenous IgG production, but
when the impact of therapy for cGVHD was taken into
account the type of stem cell graft lost signiﬁcance.
Ability to recover endogenous IgG production following
treatment with rituximab after SCT depends on successful
treatment of cGVHD and in this group of patients requires
about 1 year from end of therapy. Among those treated with
rituximab whose cGVHD does not resolve and in those with
early EBV reactivation, loss of IgG production persists at least
several years. In this later group, failure to recover IgG
production may be due to other factors separate from
rituximab therapy.358
Nitazoxanide Is Effective Therapy for Norovirus
Gastroenteritis after Chemotherapy and Hematopoietic
Stem Cell Transplantation (HSCT)
Joan Morris, Christopher Morris. Pediatrics, Loma Linda
University, Loma Linda, CA
Norovirus is amajor cause of nonbacterial gastroenteritis and
is a self-limited in immunocompetent patients. However, in
immune compromised pts it causes prolonged infection,
GVHD and sepsis due to mucosal breakdown. Supportive
care is the current therapy as attempts to treat with ribavirin
or oral immunoglobulin have failed. We report our
experience treating norovirus gastroenteritis occurring in 14
patients (pts) after (11) and prior (3) to HSCT with
Nitazoxanide.
From Nov 2012 to Dec 2013, 14 pts (2 receiving chemo-
therapy, 2 auto HSCT and 10 allo HSCT) developed norovirus
gastroenteritis. Ages ranged from 1 to 21 years (median 10)
diagnoses included ALL/AML (6), aplastic anemia (2), Wiskott
Evaluable Patients (N¼30)
Age at enrollment (years)
Mean(SD) 7.7 (4.7)
Median (range) 6.9 (2.2-17.3)
Age at enrollment (years)
2-3.99 10 (33%)
4 or older 20 (67%)
Stem Cell Source
Cord blood 5 (16%)
Marrow 21 (70%)
Marrow and cord blood 1 (3%)
PBSC 3 (10%)
Stage of Acute GI GVHD for





Overall Grade of Acute GVHD for
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medulloblastoma. Norovirus was detected by RNA RT-PCR
test of stool performed by Focus Diagnostics, Cypress, Ca. The
dose of Nitazoxanide was 100mg po BID for ages 1 to 4 years,
200 mg po BID for age 4 to 11 years, and 500 mg po BID for
greater than 11 years.
1 pt, 33 months post allo HSCT with normal immune
studies was not treated as symptoms resolved prior to test
result. All other pts clinically responded with improvements
in diarrhea, nausea, and abdominal pain in 2-4 days (median
2 days). 3 pts were pre-HSCT on chemo/immunotherapy and
11 were 17 days to 34 months after HSCT. All the treated pts
were on immune suppression or chemotherapy. 9 allo HSCT
pts were on immunosuppression and 5 of these had GVHD at
onset of symptoms. Immune suppression included tacroli-
mus/solumedrol (3), cellcept/solumedrol (2) plus inﬂiximab
(1), tacrolimus (1), cyclosporine (1), tacrolimus/cellcept (1). 3
pts were receiving immunotherapy (1), or chemotherapy for
solid tumors (2) prior to planned HSCT. 1 pt was 10 months
post auto HSCT. Clearance of stool virus was variable. 2/3 pts
treated prior to HSCT became negative on stool study within
5-14 days of treatment (1 unknown duration). Among pts
treated after HSCT 4/9 had persistent viral shedding, 2
received drug until death (1 adenovirus, 1 CHF) both were
treated greater than 2 months, 3 with GVHD still shed virus
after 6 months of treatment, and 4 are off therapy and
remain negative for norovirus RNA. 1 auto HSCT pt stopped
viral shedding 2 months post starting Nitazoxanide. 2 HSCT
pts with clinical resolution but persistent viral shedding
stopped treatment and had clinical symptoms return. These
pts responded to restarting therapy within 2 days but
continue to shed virus. UGI endoscopy/colonoscopy were
performed in 5 pts at the time of infection, all showed
inﬂammation/edema but no GVHD was seen on histology.
Peripheral blood CD4 counts among those with persistent
viral shedding ranged from <50-445/ul and for those that
cleared virus 143-1222/ul.
Nitazoxanide is effective therapy for norovirus gastroen-
teritis in immune compromised patients. Therapy needs to
be continued until stool RNA studies become negative.359
Safety and Feasibility of Administering Lactobacillus
Plantarum to Children Undergoing Myeloablative
Hematopoietic Cell Transplantation (HCT)
Michael L. Nieder 1, Elena J. Ladas 2, Monica Bhatia 3,
Michael Gates 4, Frances Hamblin 5, Aleksandra Petrovic 6,
Lu Chen 7, Eric Sandler 8. 1 Blood and Marrow Transplantation,
H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL;
2 Division of Pediatric Hematology/Oncology/Stem Cell
Transplant, Columbia University, New York, NY; 3 Division of
Pediatric Hematology, Oncology, and Stem Cell Transplantation,
Department of Pediatrics, Columbia University, New York, NY;
4 Pediatric Hematology/Oncology/BMT Research, All Children's
Hospital Johns Hopkins Medicine, St. Petersburg, FL; 5 All
Children's Hospital Johns Hopkins Medicine, St. Petersburg, FL;
6 Blood and Marrow Transplant, All Children's Hospital Johns
Hopkins Medicine, St. Petersburg, FL; 7 Preventive Medicine,
Children's Oncology Group Statistical Data Center and
University of Southern California, Monrovia, CA; 8 Nemours
Children's Clinic, Jacksonville, FL
Myeloablative regimens are associated with prolonged
periods of cachexia/anorexia, nausea/vomiting, mucositis,
and compromised gut integrity (CGI). Studies suggest that
CGI could increase the risk of developing acute Graft versus
Host Disease (aGVHD). Preserving gastrointestinal integritymay decrease the risk of aGVHD which occurs in approxi-
mately 35% of children undergoing allogeneic HCT. Probiotics
(nutritional supplements that contain viablemicroorganisms
and confer a beneﬁt to the host) have emerged as a possible
therapeutic agent in preserving gut integrity. Animal studies
have found that administration of probiotics reduced the
incidence of aGVHD when compared to placebo. Clinical
trials in children with HIV infections and adults receiving
organ transplants have found probiotics to reduce morbidity
andmortality. Prior to our Pilot Trial, probiotics had not been
investigated in the HCT setting. This pilot study evaluated the
safety and feasibility of probiotics administered to children
undergoing allogeneic HCT. Patients received once daily
supplementationwith L.plantarum 299v (1 x107 CFU/kg/day)
beginning on Day e 7 and continued until Day + 14. Thirty-
one patients who were undergoing myeloablative allogeneic
HCT were enrolled. One patient was not evaluated for safety
because only one dose was given and the patient withdrew
from the study. Safety: Of 30 evaluable patients, there were
no cases of Lactobacillus plantarum bacteremia (0% (0/30)
with 95% exact binomial CI (0%, 12%)). Feasibility: Of the 31
eligible patients, only one (#12) received < 50% of the dose.
Therefore, 97% of the eligible patients (30/31), 95% CI (83%-
100%), received at least 50% of the probiotic dose. Clos-
tridium difﬁcile infections were noted in 20% of the patients
by Day + 100. Non-lactobacillus bacteremia was noted in 23%
of evaluable patients. Three patients died before Day + 100,
but no deaths were associated with lactobacillus adminis-
tration. Stage 1-3 acute gastrointestinal aGVHD was noted in
22% of patients who survived to Day + 100. The overall
incidence of Grades II-III GVHD was 26%. No patients had
Grade 4 GVHD. Lactobacillus plantarum can safely and
feasibly be administered to children undergoing myeloa-
blative HCT.360
Clostridium Difﬁcile Infection in Patients Undergoing
Hematopoietic Cell Transplantation. Results from the
Transplantation Group at the Catholic University Hospital
in Santiago, Chile
Javier Pilcante, Patricio Rojas, Daniel Ernst, Mauricio Sarmiento,
Mauricio Ocqueteau, Pablo Bertin, Maria Jose Garcia,
Maria Alejandra Rodriguez, Veronica Jara, Pablo A. Ramirez.
